• Treatment-related AEs were few and mostly mild transient application-site pruritus (tirbanibulin vs. vehicle: 9% vs. 6% and pain (tirbanibulin vs. vehicle: 10% vs. 3%). No deaths, discontinuations, or serious AEs related to tirbanibulin were reported.

REFERENCES

CONFLICTS OF INTEREST
BB has served as a consultant, speaker, and/or investigator for Almirall, Böhringer, LED, and Pierre Fabre, and also participated in the US Böhringer PCT Advisory Council. AA has served as a consultant for Almirall. AF, SF, LP, and FR are employees of Almirall.

Table 2. Logistic regression model at Day 57 (ITT population)

Table 3. Clearances rates at Day 57 by previous AK treatment (ITT population)

Table 4. Clearances rates at Day 57 by Fitzpatrick skin type (ITT population)

Table 5. BMI by clearances rates at Day 57 (ITT population)

Figure 1. Evolution of facial AK lesions in patients who showed complete clearance with tirbanibulin at Day 29 (A) and Day 15 (B)